Tackling the Legal Challenges Being Faced by Life Sciences Companies in the COVID-19 Fight

July 29, 2021 12:30pm

Tara K. Giunta
Paul Hastings LLP

Elizabeth Feeney
Vice President, Assistant General Counsel

Donna Meuth
Associate General Counsel, Intellectual Property

Ana C. Ward
Deputy General Counsel - Legal Strategic Transactions
Astellas Pharma US

  • Gauging the continued impact of COVID-19 across global life sciences markets
  • Examining the legal implications of companies mobilizing around the rapid production of Covid cures, treatments and preventatives
  • Addressing sustainability / ESG concerns relevant to life sciences companies
  • Analyzing recent changes to FDA approval processes, the use of Emergency Use Authorizations (EUAs), and future potential implications on product liability cases
  • How do we expect PREP Act immunity to be applied and interpreted in cases moving forward?
  • Exploring legal challenges related to equitable distribution of vaccines, and the potential impact that government use provisions, “march in rights” and compulsory licensing laws will have on life sciences companies developing pharmaceuticals and medical devices to address the ongoing pandemic